SGMT

+ Watchlist + Portfolio

Sagimet Biosciences Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.58
52-Week Range: $4.50 – $11.15
Market Cap: $632.78M
P/E (TTM): —
EPS (TTM): -1.21
Dividend Yield: —

Advanced Metrics

Price/Book: 3.24
PEG Ratio: —
Return on Equity: -24.37%
Return on Assets: -16.41%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 45.02
Debt/Equity: 0.01
Total Debt: $1.94M
Free Cash Flow: $-27.82M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $394.59M

SGMT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$2.00M	$0.00	$0.00
Research & Development	$24.92M	$19.78M	$38.44M	$39.05M
Selling, General & Admin	$6.14M	$12.96M	$16.01M	$17.84M
Operating Expenses	$31.05M	$32.74M	$54.45M	$56.89M
Operating Income	-$31.05M	-$30.74M	-$54.45M	-$56.89M
EBITDA	-$31.05M	-$30.74M	-$54.45M	-$56.89M
Pretax Income	-$30.50M	-$27.88M	-$45.57M	-$51.04M
Net Income	-$30.50M	-$27.88M	-$45.57M	-$51.04M
Diluted EPS	-1.38	-2.66	-1.45	-1.58
Diluted Shares	22.17M	10.46M	31.35M	32.35M

SGMT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$158.00K	$75.14M	$75.84M	$35.02M
Current Assets	$32.79M	$96.65M	$152.77M	$116.40M
Total Assets	$33.03M	$96.72M	$160.26M	$116.48M
Current Liabilities	$5.28M	$5.65M	$4.45M	$5.10M
Total Debt	$211.00K	$65.00K	$78.00K	$78.00K
Total Liabilities	$219.98M	$5.65M	$4.45M	$5.10M
Retained Earnings	-$221.87M	-$249.74M	-$295.31M	-$346.35M
Shareholders' Equity	-$186.95M	$91.06M	$155.81M	$111.38M
Working Capital	$27.51M	$90.99M	$148.32M	$111.30M

SGMT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.49M	-$23.77M	-$42.44M	-$45.65M
Free Cash Flow	-$24.49M	-$23.77M	-$42.44M	-$45.65M
Stock-Based Compensation	$1.88M	$4.99M	$5.29M	$6.45M
Investing Cash Flow	-$32.01M	$12.58M	-$61.68M	$4.56M
Financing Cash Flow	-$73.00K	$86.17M	$104.82M	$275.00K
Net Change in Cash	-$56.57M	$74.98M	$701.00K	-$40.82M

SGMT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.34M	$7.25M	$9.73M	$6.73M	$7.00M
Selling, General & Admin	$4.52M	$4.68M	$4.60M	$4.03M	$4.72M
Operating Expenses	$19.86M	$11.93M	$14.33M	$10.77M	$11.71M
Operating Income	-$19.86M	-$11.93M	-$14.33M	-$10.77M	-$11.71M
EBITDA	-$19.86M	-$11.93M	-$14.33M	-$10.77M	-$11.71M
Pretax Income	-$18.18M	-$10.39M	-$12.91M	-$9.57M	-$10.65M
Net Income	-$18.18M	-$10.39M	-$12.91M	-$9.57M	-$10.65M
Diluted EPS	-0.56	-0.32	-0.40	-0.29	-0.33
Diluted Shares	32.20M	32.20M	32.46M	32.52M	32.56M

SGMT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$64.72M	$42.33M	$32.50M	$35.02M	$36.63M
Current Assets	$146.07M	$127.20M	$119.48M	$116.40M	$107.72M
Total Assets	$146.17M	$137.41M	$128.40M	$116.48M	$107.75M
Current Liabilities	$7.18M	$7.25M	$9.15M	$5.10M	$5.30M
Total Debt	$39.00K	$152.00K	$115.00K	$78.00K	$39.00K
Total Liabilities	$7.18M	$7.25M	$9.15M	$5.10M	$5.30M
Retained Earnings	-$313.49M	-$323.87M	-$336.78M	-$346.35M	-$357.00M
Shareholders' Equity	$138.99M	$130.16M	$119.25M	$111.38M	$102.46M
Working Capital	$138.89M	$119.95M	$110.33M	$111.30M	$102.42M

SGMT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.54M	-$9.10M	-$10.18M	-$11.83M	-$8.61M
Free Cash Flow	-$14.54M	-$9.10M	-$10.18M	-$11.83M	-$8.61M
Stock-Based Compensation	$1.47M	$1.60M	$1.69M	$1.69M	$1.84M
Investing Cash Flow	$3.41M	-$13.29M	$75.00K	$14.36M	$10.22M
Financing Cash Flow	$0.00	$1.00K	$274.00K	$0.00	—
Net Change in Cash	-$11.12M	-$22.39M	-$9.83M	$2.52M	$1.60M

Market Snapshot

About

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis and other metabolic diseases. The company uses novel therapeutic approaches targeting fatty acid metabolism. Sagimet is advancing multiple drug candidates through clinical trials.